Equity Overview
Price & Market Data
Price: $0.0777
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $22,987,522
Daily Volume: 0
Performance Metrics
1 Week: 5.14%
1 Month: -19.19%
3 Months: 14.10%
6 Months: 16.14%
1 Year: 157.7%
YTD: 13.10%
Company Details
Employees: 18
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.